Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
Symbol MAGEA3 contributors: mct/npt - updated : 04-06-2020
HGNC name melanoma antigen family A, 3
HGNC id 6801
corresponding disease(s)
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
tumoral     --over  
in breast cancer, melanoma, advanced gastric carcinomas and hepatocellular carcinomas, squamous cell carcinoma of head and neck, malignant myeloma
constitutional     --low  
results in Tp53 transcriptional induction, also through reciprocal histone acetylation and methylation modifications (Zhu 2008)
tumoral     --over  
by promoter hypomethylation up-regulates its expression in colorectal carcinomas as well as in gastric cancers and might play a significant role in the development and progression of colorectal carcinomas (Kim 2006)
tumoral     --over  
GPC3, MAGE1A and MAGEA3 were increased with advanced tumor stage, size, and nodule numbers in Hepatocellular Carcinoma
tumoral     --over  
is associated with worse overall survival in undifferentiated pleomorphic sarcoma/myxofibrosarcoma (UPS/MFS)
tumoral     --over  
in bladder cancer and especially in tumours of high stage and grade
Variant & Polymorphism
Candidate gene aberrant methylation patterns of MAGEs CpG islands using methylation-special PCRs may be useful for diagnosis of hepatocellular carcinoma
  • MAGEA3, MAGEB4, and ODF4 may be particularly useful for diagnostic and surveillance of bladder transitional cell carcinoma (TCC) in the form of a multi-biomarker panel
  • MAGEA3 expression may serve as an independent marker of poor prognosis in patients with non-small cell lung cancer (NSCLC)
  • Therapy target
    may serve as an immunotherapeutic target for Cancer stem cells (CSCs) of bladder cancer